Stem cell therapy for Parkinson's disease: where do we stand?

Forskningsoutput: TidskriftsbidragÖversiktsartikel

Standard

Stem cell therapy for Parkinson's disease: where do we stand? / Roybon, Laurent; Christophersen, Nicolaj; Brundin, Patrik; Li, Jia-Yi.

I: Cell and Tissue Research, Vol. 318, Nr. 1, 2004, s. 261-273.

Forskningsoutput: TidskriftsbidragÖversiktsartikel

Harvard

APA

CBE

MLA

Vancouver

Author

Roybon, Laurent ; Christophersen, Nicolaj ; Brundin, Patrik ; Li, Jia-Yi. / Stem cell therapy for Parkinson's disease: where do we stand?. I: Cell and Tissue Research. 2004 ; Vol. 318, Nr. 1. s. 261-273.

RIS

TY - JOUR

T1 - Stem cell therapy for Parkinson's disease: where do we stand?

AU - Roybon, Laurent

AU - Christophersen, Nicolaj

AU - Brundin, Patrik

AU - Li, Jia-Yi

N1 - The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Wallenberg Neuroscience Centre, Lund (0131000110), Neuronal Survival (013212041), Neural Plasticity and Repair (013210080)

PY - 2004

Y1 - 2004

N2 - A major neuropathological feature of Parkinson's disease (PD) is the loss of nigrostriatal dopaminergic neuron. Patients exhibit motor symptoms, including bradykinesia, rigidity, and tremor. Neural grafting has been reported to restore striatial dopaminergic neurotransmission and induce symptomatic relief. The major limitation of cell replacement therapy for PD is the shortage of suitable donor tissue. The present review describes the possible sources of cells, including embryonic stem cells and somatic adult stem cells, both of which potentially could be used in cell therapy for PD, and discusses the advantages and disadvantages of each cell type.

AB - A major neuropathological feature of Parkinson's disease (PD) is the loss of nigrostriatal dopaminergic neuron. Patients exhibit motor symptoms, including bradykinesia, rigidity, and tremor. Neural grafting has been reported to restore striatial dopaminergic neurotransmission and induce symptomatic relief. The major limitation of cell replacement therapy for PD is the shortage of suitable donor tissue. The present review describes the possible sources of cells, including embryonic stem cells and somatic adult stem cells, both of which potentially could be used in cell therapy for PD, and discusses the advantages and disadvantages of each cell type.

KW - Parkinson's disease

KW - Neural grafting

KW - Embryonic stem cells

KW - Somatic adult stem cells

U2 - 10.1007/s00441-004-0946-y

DO - 10.1007/s00441-004-0946-y

M3 - Review article

VL - 318

SP - 261

EP - 273

JO - Cell and Tissue Research

T2 - Cell and Tissue Research

JF - Cell and Tissue Research

SN - 1432-0878

IS - 1

ER -